Tara Carr is a Rheumatology/Immunology physician.
Overview
Scholarship
indexed output and impact (OpenAlex)Research metrics aren't shown for this record. Either we found no confident publication match for this name, or more than one physician shares the matched author record. We'd rather show nothing than someone else's numbers. Why? →
Clinical & industry
trials, payments and federal fundingContact
The practice address and phone this provider lists in the federal NPPES (CMS) registry.
Practice address
3838 N Campbell Ave Bldg 2
Tucson, AZ 85719
Telephone
520-694-1000Registry record last updated 25 Jul 2018.
Industry payments
16 companies reported payments to CMS in program years 2021 onward. These are public disclosures, not judgments. The latest:
- DePuy Synthes Sales Inc.Program year20251 payment
- AstraZeneca Pharmaceuticals LPProgram year20256 payments
- Takeda Pharmaceuticals U.S.A., Inc.Program year20256 payments
Payment records matched to this physician's NPI in CMS Open Payments, program years 2021 onward.
Medicare prescribing footprint (2024)
The drugs this prescriber writes for Medicare patients, grouped by drug class and therapeutic area. Every percentage is a share of their total prescribing, so you can see what they prescribe most. These are proportions, not patient counts or dollar amounts. No condition is inferred: the claims record what was prescribed, never why.
Respiratory
65.5%Corticosteroid27.8%Fluticasone Propionate27%Symbicort24%Breo Ellipta19%Arnuity Ellipta16%Trelegy Ellipta8%Qvar Redihaler6%Part D<11 patientsbeta2-Adrenergic Agonist13.1%Albuterol Sulfate Hfa100%Part D≥25 patients+ 5 more classes in this area
Dermatology
13.4%Interleukin-4 Receptor alpha Antagonist9.7%Dupixent Syringe64%Dupixent Pen36%Part D<11 patientsCorticosteroid3.7%Triamcinolone Acetonide100%Part D<11 patientsMetabolism & gastrointestinal
12.7%Corticosteroid6%Prednisone100%Part D≥23 patientsProton pump inhibitor4.2%Omeprazole60%Pantoprazole Sodium40%Part D<11 patients+ 1 more class in this area
Drug classes come from the WHO ATC and U.S. National Library of Medicine (RxClass) classifications; prescribing counts come from the CMS Medicare Part D Prescribers file. Each drug is counted once, under its primary class. Medicare fee-for-service only, so no Medicare Advantage, commercial, or pediatric prescribing is included. CMS publishes this data about 17 months after the fact.
NIH funding
3 NIH research awards on record, funded 2021–2026 per NIH RePORTER. The latest:
- Diet, microbiome and genetics at the beginning of asthma: the BEAMS birth cohort
University of Arizona
FY2026$1,824,273P01AI148104
Awards in the NIH RePORTER records where a principal investigator name matches this physician at an organization in their practice state. Latest award years shown; each row links to the project record on RePORTER.
Similar KOLs
Other experts from the same institution or the same specialty.
David J. Hunter
The University of Sydney
Aziz Sheikh
Universiti Malaysia Terengganu
Nima Hafezi‐Nejad
The University of Sydney
Gelin Xu
Second Affiliated Hospital of Nanjing Medical University
A basic profile from our physician directory: identity and practice contact from the federal NPPES registry, research from OpenAlex, trials from ClinicalTrials.gov, payments from CMS Open Payments — shown itemized where we have matched records, as a count where we only have a total. This person hasn't been through our full identity-adjudication pipeline yet, so funding, congress activity and public presence aren't shown. Absence of a section means “not yet looked,” never “none found.”